Tumor cell anabolism and host tissue catabolism-energetic inefficiency during cancer cachexia

Impact statement

Cancer cachexia is a sequela of catabolism leading to poor muscle strength, reduced locomotion, weight loss, and intolerance to therapy. Greater than 80% of advanced cancer patients display cachexia, and it is a major cause of cancer-related deaths. Cancer cells harbor host tissue metabolism by secretory molecules and cargo packaged extracellular vesicles (EVs), and skew the entire host metabolism toward catabolism while themselves being anabolic. Currently, there is no standard therapy available that can effectively reverse cancer-related cachexia. Therefore, robust preclinical research in the context of etiology, initiation, progression, and therapy followed by robust clinical validation are warranted. In this regard, our present review discusses the imbalance of host metabolism, early changes during precachexia, and highlights the molecular pathways. In addition, we shed a light upon current diagnostic and therapeutic challenges associated with cancer-associated cachexia.

Introduction

Reprogramming of metabolism is one of the crucial hallmarks of cancer. ¹ Elevated glycolysis, hepatic gluconeogenesis, lipolysis, and proteolysis of skeletal muscles result in reduced body fat and progressive weight loss in cancer patients. ¹ This systemic tissue wasting sequela termed CC diminishes locomotion leading to poor quality of life, poor prognosis, and increased mortality. More than 80% of advanced-stage cancer patients display cachexia, and it accounts for about 25% of cancer-related deaths.^2,3 Nearly 30% of the CC patients have associated cardiac disorders with the risk of developing cardiac cachexia. ⁴ Cachexia might be present in the early-stage development of cancer even before the onset of signs and symptoms of malignancy. ² Initially, cachexia was thought to be a muscle protein and fat depletion metabolic disorder.^5,6 However, recent studies have established that cachexia is a multifactorial pathological condition associated with hypoxia, tissue pH, anorexia, altered metabolism, and chronic inflammation.^6,7 Hypoxia-inducible factor 1-α (HIF-1α) and hypoxia-inducible factor 2-α (HIF-2α) have been revealed to stimulate CC through diverse mechanisms comprising loss of appetite, activation of phosphoenolpyruvate carboxykinase (PEPCK), and the Cori cycle.^8,9 Indeed, pro-inflammatory cytokines such as tumor necrosis factor–alpha (TNF-α) and interleukin-6 (IL-6) were shown to be elevated in various CC in vitro and in vivo models and are proposed to be diagnostic markers of CC.^8,10–12 Studies conducted by Oliff et al. ¹³ and Baltgalvis et al. ¹⁴ demonstrated that supraphysiological IL-6 and TNF-α levels led to early CC and deaths in animal models. So far, monotherapies targeting numerous inflammatory cytokines have failed to efficaciously treat CC, owing to its multifactorial landscape.^15–17 Two independent studies by Stovroff et al. ¹⁸ and Vaisman and Hahn ¹⁹ demonstrated that TNF-α induces corticotrophin-releasing hormone, and it increases the firing of glucose-sensitive neurons leading to anorexia followed by cachexia. Furthermore, the cytokine surge is known to induce depression-induced anorexia, lipolysis via Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3), and Nuclear factor kappa- light chain enhancer of activated B cells (NF-κB) pathways and β-adrenergic activation connect CC with the central nervous system (CNS).^20,21 Nevertheless, loss of appetite is not a primary cause of cachexia during cancer progression, as the accompanying engrossment of massive skeletal muscle wasting does not occur during anorexia, and nutritional supplementation fails to impede loss of lean body mass.^22–24 Currently, the precise mechanisms that promote and govern CC are yet to be deduced, thereby limiting the therapeutic targets for the treatment of CC. Therefore, the current review provides in-depth information about spatio-temporal changes in tissue microenvironment and systemic metabolism during the initial stages of CC development. We also focus on the energetics of the cancer cell and surrounding stromal microenvironment, rate-limiting steps, and the mechanism of absconding checkpoints. Furthermore, we provide a comprehensive overview of molecular insights into tumor cell anabolism and normal tissue catabolism status during progressive CC. Finally, we highlight the current difficulties and complications in the early diagnosis and treatment of CC.

Spatio-temporal changes during cachexia progression in cancer patients

CC is divided into three successive clinical stages such as precachexia, cachexia, and refractory cachexia (RC), although not all the patients progress through this continuum.^21,22 The degree of clinical manifestations and the condition of patients, including locomotory index and probable survival period, are taken into account while staging the disease. ³ The staging of CC has crucial implications for management and treatment which go beyond merely an understanding of alleviating symptoms.

RC

RC is notable for its poor World Health Organization (WHO) physical performance score and survival expectancy of <3 months, and these patients are suited only for psychosocial support and palliative care. ³ The severity of cachexia increases as the disease progresses to metastasize. Bodyweight and circulating albumin (ALB) levels of patients with RC were significantly lower compared to patients with CPC while C-reactive protein (CRP) was found to be profoundly increased in these patients.^44,45 Recently, Suno et al. ⁴⁶ demonstrated that increased plasma fentanyl levels could be the biomarker for RC. In this study, the authors analyzed the fentanyl levels and hence the exclusion criteria of the patients selected in the study was use of drugs, as supportive therapy, that might affect the metabolism of CYP3A4, and antipsychotic drugs. Suno and co-workers have shown the remarkable association of dose-adjusted fentanyl concentrations with refractory cancer cachexia. RC is significantly associated with cardiac atrophy, arrhythmias, and electrolyte imbalance that increase the risk of thromboembolic events, cardiac arrest, breathing difficulties, aspiration pneumonia, swallowing difficulties, reduced joint movements, gastrointestinal muscle atrophy, poor wound healing, and sepsis. Not surprisingly, clinical data showed high mortality within a few weeks of the development of RC. ⁴⁷

The detailed differences between CPC, CC, and RC are summarized in Table 1.^{14,30,31,35,37,44,46,48–73}

OPEN IN VIEWER

Table 1.

Characterization of different phases of cachexia.

Condition/molecule	Precachexia	Cachexia	Refractory Cachexia	Reference
Fat loss	↔	↓	↓↓	44,48
Muscle strength, contractility	↓	↓	↓↓	48,49
Food intake and appetite	↔	↓	↓↓	44
Protein synthesis	↔	↓	↓↓	51
Protein degradation	↔	↑	↑↑	51
Regeneration	↔	↓	↓↓	52,53
Atrogenes (Atrogin-1 and MuRF-1)	↔	↑	↑	31
Ubiquitin protein ligase	↔	↑	↑	35,37
Cell cycle and myogenesis	↓	↔	?	30,55
Apoptosis	?	↑	↑	14,54,55
Autophagy	↔	↑	↑	30,56,73
Mitophagy	↔	↑	↑	57,58
ATP production	↔	↑	↑	59
Inflammation	↑	↑↑	↑	60,61
TNF-α, IL-6, IL-1β, neuropeptide Y	↑	↑↑	↑	54,62,63
CRP	?	↑	↑↑	46
MAPK	?	↑	↑	63,71
NFκB	?	↑	↑	64,65
STAT3 signaling	↑	↑↑	↑	66
ROS	↑	↑	↑	67,68
Calcium homeostasis	?	↑	↑	69,70
Oxidative stress	↑	↑	↑	71
Mitochondrial fission	↔	↑	↑	72,73
Mitochondrial fusion	↓	↓	↓	73

ATP: adenosine triphosphate; TNF-α: tumor necrosis factor–alpha; IL-6: interleukin-6; CRP: C-reactive protein; MAPK: mitogen activated protein kinase; STAT3: signal transducer and activator of transcription 3; ROS: reactive oxygen species.

↔: unaltered; ↑: increased; ↓: decreased; ?: not reported.

Energetics of cancer cells and host tissues

Increased catabolism is observed in cancer patients leading to unsustainable muscle and fat loss, thereby causing high morbidity and mortality.^7,74 The factors such as old age, tumor progression, comorbid conditions, nutritional deficiency, drugs, and medical interventions were found to be the major determinants of the resting energy expenditure (REE). ⁷⁵ Tumors demand a continuous supply of glucose and energy for their uninterrupted growth and proliferation and alter the energy balance of host tissue by eliciting inflammatory pathways which augment both systemic and locally mediated catabolic events. ⁷⁶ Tumors also consume the increased amount of macronutrients directly. When tumors reach the size >0.75 kg, the energy consumption by the tumor is quantitatively important. ⁷⁴ The average daily energy expenditure of cancer patients is between 1600 and 1800 kCal. ⁷⁷ Lieffers et al. ⁷⁸ demonstrated that in metastatic colorectal cancer patients, there is a cumulative increment in REE which accounts for about ~17,700 kCal over 3 months, and this high demand of REE itself can contribute to a substantial reduction in body weight. In this study, the authors have tried to link the REE to energetically demanding tissues such as liver, spleen, skeletal muscles, adipose tissues, and tumor mass with advanced cancer and cancer cachexia–associated weight loss. Another mechanism that amplifies catabolic signals while desensitizing muscles to anabolic signals is physical inactivity; for instance, Kortebein et al. ⁷⁹ reported that bed rest for 10 days causes a 6% loss in lower limb muscle, a 30% drop in muscle protein synthesis, and a 16% loss in isokinetic muscle strength in otherwise healthy adults over 65 years of age. Bed rest elevates catabolic responsiveness of the muscles to cortisol by threefold. ⁸⁰ Muscle anabolism was induced by physical exercise in these patients and though fatigue was not reduced, quality of life was improved. ⁸¹ Although bed rest in healthy elderly subjects leads to signs and symptoms of disuse atrophy, more studies are needed to understand the molecular mechanisms governing disuse atrophy and CC, and exploring whether they are similar or not.

Imbalance of anabolism and catabolism: insight into the molecular level

Our present understanding of the basic mechanisms that promote CC is based on three lines of experimental evidence. First, Ni et al. ⁸² demonstrated that surgical removal of cachexia-related tumors entirely (when practicable) could reverse CC in pancreatic xenograft models. Tumors are thus required not only for the induction of cachexia but also for its maintenance. Second, Norton et al. ⁸³ showed pro-cachectic factors could be transferred between tumor-bearing rats to non-tumor-bearing rats when both are connected surgically via circulation, indicating the humoral nature of these circulatory factors. Succeeding investigations showed that humoral factors are secreted either directly by cancer cells or by stromal cells in the tumor microenvironment, or by distant organs. Primary tumors, as well as metastatic cachexia models, have revealed that cachexia-induced circulating components include hormones, growth factors, metal ions, and both pro- and anti-inflammatory cytokines.^84,85 Third, these circulating factors cause cachexia by two separate pathways, either directly by interacting with myocytes and activating muscle catabolic pathways and by restricting muscle protein synthesis, or indirectly through metabolic changes in secondary organs, which leads to muscle atrophy.^84–86 Table 2 summarizes the mechanism of cachexia.^{13,14,34,87–124} The broad picture of CC is summarized in Figure 1.

OPEN IN VIEWER

Table 2.

Cancer cachexia models and mechanisms.

Cancer type	In vitroIn vivo	Model	Mechanism of action or outcome	References
Breast cancer	Ex vivo	Tissue samples	↑FATP1, CD36, UCP1, p-p38, ↓PPARγ, p-PPARγ	87
	In vitro	C2C12 cells treated with exosomes from MCF-7 and MDA-MB-231 cells	↑UCP3, p-p38, exosomal miR-155, ↓PPARγ, p-PPARγ, p-ERK1/2	87
	Ex vivo	Tissue samples	↑gelsolin, calponin2, tropomyosin 2, vimentin, P4HAI, PKM2 annexin A1, annexin A2, ARHGDIB, PGK1, LDHA, ALDOA, GPD2, ENO1, TPI1, PGAM1, EEF1D, PRDX1, CAT, tenascin C, SPARC, COL1A1, COL1A2, alpha fetoprotein, metastasis tumor recurrence, ↓Cav-1, survival	88
	In vitro	Cav-1 deficient fibroblasts	↑PKM2, LDHA, reactive oxygen species	88
	In vitro	MCF-7	↑leptin, mitochondrial respiration, PYC, G6PD, cell proliferation	89
Colorectal cancer	In vitro	H9c2 cells	↑Oxidative stress ↓Basal, maximum and spare respiration, ATP, mitochondrial membrane potential and volume	90
	In vivo	Mouse cachexia model	↑4-HNE ↓cardiac weight, myocardial area, ATP, SDS-MYL1	90
	Ex vivo	Plasma	↑exosomes	91
	In vitro	Exosomes from CT26	↑IL-6, atrogin-1, MURF1, myotube atrophy, ↓myotube diameters	91
	In vitro	C2C12 myoblasts	↑IL-6, atrogin-1	92
	In vivo	ApcMin/+ mouse	↑IL-6, atrogin-1, gastrocnemius muscle wasting	14
	In vivo	C26 mouse model	↑LIF, STAT3, p-STAT3, atrophy of myotubes	14
	In vivo	C26, ApcMin mouse model	↑IL-6, STAT3, p-STAT3, atrophy of muscle fiber	92
	In vivo	ApcMin mouse model	↑IL-6, p-AMPK, ↓ mTOR	93
	In vivo	C26 mouse model	↑LC3bII/LC3BI, p62, muscle atrophy	94
	In vivo	C26 mouse model	↑Pax7, p65, delayed muscle regeneration	95
	In vivo	C26 mouse model	↑UCP1, PBE, CPT1α, BAT temperature	96
	In vitro	3T3-L1	↑ZAG, p62, muscle fiber atrophy	97
	In vivo	MAC16 mouse model	↑ZAG, weight loss, lipolysis	97
	In vivo	MAC16 and MAC13 mouse model	↑FDG uptake, succinate level, phosphocholine, weight loss, MURF1, Serum LDL	98
	In vitro	C26 conditioned C2C12 myoblasts	↑Ddit4/REDD1, Akt1, mTOR, LC3 II, p62 ↓p-Akt1, p-mTOR, p-4E-BP1, p-p70S6K	99
	In vivo	C26 xenograft model	↑Ddit4, Akt1, Akt2, PDPK1 ↓p-Akt1, p-mTOR, p-4E-BP1, p-p70S6K	99
	In vitro	C26 conditioned AML2	↓mitochondrial membrane potential, H2O2 production, MFN2, DRP1, FIS1, PINK	34
	In vivo	HCT-116 mouse model	↑exosome density, miR-146b-5p, UCP1, PRDM6 ↓leptin, ADIPSIN	100
	In vivo	C26 mouse model	↑exosomes, miR-195a-5p, miR-125b-1-3p, muscle atrophy ↓Bcl-2	101
Kidney cancer	In vitro	RXF393, SKRC39, A498, 786-O, SN12C	↓MyoD1, pan-MHC, mTOR, TGF-β	102
	In vivo	RXF393, SKRC39, A498, 786-O, SN12C mouse model	↓MyoD1, glycolytic signatures, body weight ↑lipolysis, p38 MAPK	102
Lung cancer	Ex vivo	serum	↑TNF-α, ROS, GSH, vitamin E, IL-6	91
	In vitro	Exosomes from LLC	↑IL-6, atrogin-1, MURF1, myotube atrophy, ↓myotube diameters	91
	In vivo	LLC cells	↑gp130, STAT3, p-STAT3, atrogin-1, p38	103
	In vitro	PC-3, H1299	↓cavin-3, p-ERK, EGFR1, glucose uptake, lactate production ↑p-Akt, HIF1α, pS6K, survivin	104
	In vivo	Mouse fetus	↓cavin-3, p-ERK, PTEN, body weight ↑p-Akt, HIF1α, glycolysis, lipodystrophy	104
	In vitro	LLC conditioned C2C12 myoblasts	↑REDD1, ↓ myotube diameter, muscle loss, p-Akt1, p-mTORC1	105
	In vitro	Extracellular vesicles from LLC	↑lipolysis, p-HSL, UCP1, PTHrP	106
	In vivo	C57BL/6	↑lipolysis, PTHR, PTHrP	106
	In vivo	LLC	↑IL-6, STAT3, atrophy ↓muscle weight, fat weight, BM-MNCs, NFATc1	107
	In vivo	LLC	↑RAGE, S100B, HMGB1, IL-6, IL-3, IL-9, IL-12p40, IL-17A, IFNγ, TNF-α, splenomegaly, muscle wasting ↓body weight, survival, IL-1α, MyoD, MyHC	108
	Ex vivo	Patient serum, muscle biopsies	↑miR-424-5p, miR-424-3p, miR-450a-5p ↓miR-451a, miR-144-5p, muscle strength	109
	In vivo	LLC	↑SAA, IL-6 ↓PON1	110
Pancreatic cancer	In vitro	MiaPaCa2, AsPC1, BxPC3, HPAF-2, Panc-1, C2C12	↑TNF-α, IL-1β, IFN-γ	111
	In vivo	MiaPaCa2 and AsPC1 xenograft	↑PCB, G-6-Pase, skeletal muscle proteolysis, ↓myosin, body weight, hepatic glycogen, ATGL, atrogin-1, MURF1	111
	In vitro	MiaPaCa2, AsPC1	↑Cav-1, IGF1R, IR, glycolysis	112
	In vivo	MiaPaCa2 cells	↑ Cav-1, IGF1R, IR, skeletal muscle proteolysis, ↑lipolysis, ↓body weight	112
	Ex vivo	Serum	↑GLP-1, apoC-II, apoC-III	113
	Ex vivo	Serum	↑ IL-6, glucocorticoids, ↓ ketone levels, food intake	114
	In vivo	KPC	↑IL-6, glucocorticoids ↓ food intake, ketones, PPAR-α, ACADM, HMGCS2	114
	In vivo	C57BL/6J	↑LCN2, E3 ubiquitin ligase, MAFBX, MURF1, FOXO1 ↓ BNIP3, CTSL, GABARAPL, PPAR-γ, food intake	115
	Ex vivo	Human tissue	↑ IL-6, cachexia	116
	In vitro	KPC 32908, C2C12, 3T3	↑ IL-6, p-STAT3, E3 ubiquitin ligase, atrogin-1, MAFBX, TRIM63/MURF1 ↓ myotube diameter	116
	In vivo	C57BL/6	↑IL-6, muscle wasting ↓ survival	116
	In vitro	C2C12	↑atrogin-1, MURF1 ↓MyHC	117
	In vivo	C57BL/6	↑macrophage mediated STAT3 activation ↓body weight, body strength, IL-6, TNF-α, IL-1α, IL-1β	117
	In vitro	C2C12	↑Sirt1, TRIM63, FBXO32, atrogin-1, NOX4 ↓myotube width, total protein content, MyHC	118
	In vivo	KPC mouse model S2-013 orthotopic model	↑Sirt1, MURF1, atrogin-1, ZAG, UCP2, ↓body weight, forelimb grip strength, fat content, MyHC	118
	In vivo	Pan02, FC1242 bearing mice	↑ZIP4, Zinc	119
Other	In vivo	Walker 256 cells	↓response to glucagon, isoproterenol, cAMP, phenylephrine, ↓liver ATP	120
	In vivo	Walker 256 cells	↑leucine rich diet, ↓tumor FDG uptake, metastasis	121
	In vitro	C2C12 myoblasts	↑ atrogin-1, MURF1, E214k, FOXO1, USP2, UBC ↓ myoD, Pax3, p-Akt, MYH2, TNNC1, TPM3, TCAP,	122
	In vivo	Myostatin cachexia model	↓myoD, Pax3, ↑ atrogin-1, MURF1, E214k	122
	In vivo	CHO cells	↑TNF-20, weight loss, progressive death	13
	Ex vivo	Serum from cancer patients	↑ IL-15	123
	In vivo	MC38, LLC, CT26 bearing mice	↑PLA2G7	124

FATP1: fatty acid transport protein 1; CD36: cluster determinant 36; UCP1: uncoupling protein 1; p-p38: phospho p38; PPARγ: peroxisome proliferator-activated receptor gamma; p-PPARγ: phospho peroxisome proliferator-activated receptor gamma; UCP3: uncoupling protein 3; ERK: extracellular signal-regulated kinase; p-ERK: phospho extracellular signal-regulated kinase; P4HAI: prolyl 4-hydroxylase subunit alpha 1; PKM2: pyruvate kinase M2; ARHGDIB: rho GDP dissociation inhibitor beta; PGK1: phosphoglycerate kinase 1; LDHA: lactate dehydrogenase A; ALDA: aldolase, fructose bisphosphate A; GPD2: glycerol-3-phosphate dehydrogenase 2; ENO1: enolase 1; TPI1: triosephosphate isomerase 1; PGAM1: phosphoglycerol mutase 1; EEF1D: eukaryotic translation elongation factor 1 delta; PRDX1: peroxiredoxin 1; CAT: catalase; SPARC: secreted protein acidic and cysteine rich; COL1A1: collagen type 1 alpha 1 chain; COL1A2: collagen type 1 alpha 2 chain; Cav-1: caveolin 1; PYC: pyruvate carboxylase; G6PD: glucose-6-phosphate dehydrogenase; 4-HNE: 4-hydroxynonenal; ATP: adenosine triphosphate; SDS-MYL1: SDS-soluble myosin light chain 1; IL-6: interleukin-6; MURF1/TRIM63: muscle-specific RING finger protein 1/tripartite motif containing 63; LIF: leukemia inhibitory factor; STAT3: signal transducer and activator of transcription 3; p-STAT3: phospho signal transducer and activator of transcription; p-AMPK: phospho AMP-activated catalytic subunit; mTOR: mechanistic target of rapamycin kinase; p-mTOR: phospho mechanistic target of rapamycin kinase; Pax7: paired box 7; LC3bII/LC3BI: light chain 3 B 1/light chain 3 B 2; PBE: peroxisomal bifunctional enzyme; CPT1α: carnitine palmitoyltransferase 1 alpha; BAT: brown fat tissue; ZAG: zinc-alpha-2 glycoprotein; FDG: fluorodeoxyglucose; LDL: low-density lipoprotein; Ddit4/REDD1: DNA damage inducible transcript 4/regulated in development and DNA damage responses 1; Akt1: Akt serine/threonine kinase 1; p-Akt1: phospho Akt serine/threonine kinase 1; p-4E-BP1: phospho eukaryotic translation initiator factor 4E binding protein 1; p-p70S6K: P70 ribosomal S6 kinase; PDPK1: 3-phophoinositide dependent protein kinase 1; H₂O₂: hydrogen peroxide; MFN2: mitofusin 2; DRP1: dynamin-related protein 1; FIS1: fission mitochondrial 1; PINK: PTEN induced kinase; PRDM6: PR/SET domain 6; Bcl-2: B-cell CLL/lymphoma 2; TGF-β: transforming growth factor–beta; MHC: myocin heavy chain; MyoD1: myogenic differentiation 1; MAPK: mitogen activated protein kinase; TNF-α: tumor necrosis factor–alpha; ROS: reactive oxygen species; GSH: glutathione; gp130: glycoprotein 130; cavin-3: caveolae associated protein 3; EGFR1: epidermal growth factor receptor 1; HIF1-α: hypoxia inducible factor subunit alpha; pS6K: phospho S6 kinase; PTEN: phosphatase d tensin homolog; HSL: hormone sensitive lipase; p-HSL: phospho hormone sensitive lipase; PTHR: parathyroid hormone receptor; PTHrP: parathyroid hormone receptor–related protein; BM-MNCs: bone marrow–derived mononuclear cells; NFATc1: nuclear factor of activated T cells 1; RAGE: receptor for advanced glycation end product; S100B: S100 calcium binding protein B; HMGB1: high mobility group box 1; IL-3: interleukin-3; IL-9: interleukin-9; IL-12p40: interleukin-12 subunit p40; IL-17A: interleukin-17A; IFNγ: interferon gamma; IL-1α: interleukin-1 alpha; IL-1β: interleukin-1 beta; SAA: serum amyloid A1; PON1: paraoxonase 1; PCB: pyruvate carboxylase; G6pase: glucose 6 phosphatase; ATGL: adipose triglyceride lipase; IGF1R: insulin like growth factor 1 receptor; IR: insulin receptor; GLP1: glucagon like peptide 1; Apo CII: apolipoprotein C2; Apo CIII: apolipoprotein C3; PPAR-α: peroxisome proliferator-activated receptor alpha; ACADM: acyl CoA dehydrogenase medium chain; HMGCS2: 3-hydroxy-3-methylglutaryl-CoA synthase 2; LCN2: lipocalin 2; MAFBX/FBXO32: muscle atrophy F-box protein/F-box protein 32; FOXO1: Forkhead box O1; BNIP3: Bcl-2 interacting protein 3; CTSL: cathepsin L; GABARAPL: GABA type A receptor associated protein like; Sirt1: sirtuin 1, NOX4: NADPH oxidase 4; ZIP4: Zrt/Irt-like protein 4; cAMP: cyclic adenosine mono phosphate; E2_14K: ubiquitin conjugating enzyme E2 14 kDa; USP2: ubiquitin specific peptidase 2; UBC: ubiquitin C; Pax3: paired box 3; MYH2: myosin heavy chain 2; TNNC1: troponin C1; TPM3: tropomyosin 3; TCAP: titin-cap; TNF-20: tumor necrosis factor–20; IL-15: interleukin-15; PLA2G7: phospholipase A2 group 7.

OPEN IN VIEWER

Figure 1.

Mechanism of cancer cachexia. Anabolic tumor tissue continuously demands glucose, amino acids, fatty acids, and other nutrients. The cytokine storm generated from the growing mass of tumors acts on host tissue leading to catabolism and cachexia. The figure was created in BioRender.com. (A color version of this figure is available in the online journal.)

Cardiac muscle atrophy

Currently, a countable number of studies are available focusing on the effects of CC on vital organs. Cardiac muscle performs a vital role and was assumed to be spared since it cannot be exploited as amino acid or fat repository like skeletal muscles during normal physiology. Although the cardiac muscle atrophy in CC remains to be evaluated, research on animal cachexia models has shown substantial loss of cardiac muscle fibers and functional impairment of cardiac muscles by echocardiography. ⁴ In vivo studies have proved that mechanisms that contribute to cardiac muscle atrophy are similar to those in skeletal muscles including elevated protein degradation, reduced protein synthesis, inflammation, and autophagy.^175–177 Although adequate knowledge of mechanisms is lacking, it has been shown that RC is significantly associated with cardiac arrhythmias and arrest in cancer patients. ¹⁷⁵

Others

Recently, “omic” studies have been extended to find the molecular mechanisms, pathways, and promising biomarkers for CC. Integrative transcriptomic analysis of cachectic muscle and extensive bioinformatics approaches by Niu et al. ⁹⁹ revealed that 371 genes were up-regulated and 422 were downregulated with the enrichment of genes involved in extracellular matrix reorganization, muscle system processes, muscle differentiation, muscle tissue development, JAK-STAT signaling, cytokine-cytokine receptor signaling, HIF-1 signaling, and so on. Using in vitro knockdown models, authors further showed that p38 induced expression of Ddit4 which in turn inhibited phosphorylation of Akt1, mTOR, 4E-BP1, and p70SK6. ⁹⁹ Deletion of REDD1 in LLC-conditioned C2C12 myoblasts showed that elevated phosphorylation of FOXO3A, Akt1, mTORC1 prevented cachexia. ¹⁰⁵ Furthermore, knockout of lipocalin 2 (LCN2) in pancreatic cachexia mice models showed the suppression of food intake by directly acting on CNS upon crossing the blood-brain barrier. ¹¹⁵ Recently, transcriptome profiling of rectus abdominis muscle from pancreatic cancer patients showed 340 differentially expressed genes, including FOXO1, FOXO3, phosphoinositide-3-kinase regulatory subunit 1 (PIK3RI), glutamate-ammonia ligase (GLUL), interleukin-6 receptor (IL-6R), ZIP14, protein phosphatase 1 regulatory subunit 8 (PPP1R8), apoptosis enhancing nuclease (AEN), coiled-coil domain containing 68 (CCDC68), Wnt family member 9A (WNT9A), protein O-mannosyl transferase 2 (POMT2), sestrin 1 (SESN1), ring finger protein 207 (RNF207), and dystonin (DST) were found to be correlated with an increasing grade of weight loss in cancer patients. ¹⁷⁸

Diagnosis and treatment

Diagnosis of CC is challenging due to the display of multiple symptoms and accordingly, each patient must be critically evaluated for BMI, nutritional status, and locomotory index prior to the optimization of precision medicine.^3,25 Cachexia might be under-recognized in certain cases including epidemic obesity. Even at the initial time of cancer diagnosis, obese patients can have substantial ongoing muscle depletion known as sarcopenic obesity. In addition to obesity, underlying cachexia can be masked by weight gain due to ascitic fluid accumulation or peripheral edema.^74,78,179 Hence, the effective early diagnosis of cachexia includes careful monitoring of body composition, fat mass, and muscle mass. The Patient-Generated Subjective Global Assessment (PG-SGA) is an approved and validated method for malnutrition in patients with CC. ¹⁸⁰ PG-SGA contains a comprehensive questionnaire that assesses calorie intake, body weight, muscle mass, body fat mass, temperature, functional status of locomotory organs, and whether systemic or local edema is present. ¹⁸⁰ The Mini-Nutritional Assessment (MNA) is a rapid nutritional screening tool that evaluates dietary history, nutritional risk factors, body weight, and mid-arm circumference. ¹⁸¹ However, these screening tools do not measure muscle mass or composition. ¹⁸² Regularly used parameters to evaluate body composition in cancer patients include anthropometric methods, bioelectrical impedance analysis (BIA), computed tomography (CT), and dual-energy X-ray absorptiometry (DXA). The anthropometric method evaluates body composition by measuring height, weight, skinfolds, and body circumference. It is one of the oldest and simplest methods, exhibiting poor accuracy, and it cannot distinguish between fat content and lean body mass. ¹⁸³ BIA, on the contrary, can be used to assess the percentage of total body fat, fat-free mass, and to calculate body fluid based on the electrical properties. ¹⁸⁴ Nonetheless, BIA is not as accurate as DXA, which predominantly determines appendicular muscle mass. Although DXA is cost-effective and requires a very low level of radiation, it does not distinguish subsets of adipose tissues into visceral, subcutaneous, and intramuscular. ¹⁸⁵ Meanwhile, recent advancements in CT scans allow assessment of axial muscle mass. This approach offers a high level of sensitivity and specificity and is a gold standard for evaluating body composition. ¹⁸⁶ Magnetic resonance imaging (MRI) has a higher specificity and accuracy, equivalent to that of CT, in measuring the body composition, and does not expose the patients to ionizing radiation, although it is more expensive than CT.^187,188 Upper arm grip assessment, psychosocial and physical activity are the few parameters to measure muscle strength and functionality of patients with CC.^3,189 Screening for the novel biomarkers of CC is the research hotspot. A variety of inflammatory markers and cytokines are proposed to be biomarkers of CC, including hemoglobin content, ALB content, CRP, leptin (LEP), adiponectin, ghrelin, insulin-like growth factor-1 (IGF-1), IL-1, IL-6, and TNF-α.^190,191 Moreover, a few cancer patients might be less susceptible to cachexia development. For instance, cachexia is less likely in patients with a loss of function mutation in protein P selectin (SELP). ¹⁹² Recently, using an aptamer-based discovery platform, Narasimhan et al. ¹⁹³ demonstrated the expression of 71 proteins that correlated with pancreatic cancer cachexia, including known cachexia markers such as LEP, MSTN, and ALB as well as novel cachexia markers such as lymphatic vessel endothelial hyaluronan captor 1 (LYVE1), complement C7 (C7), and coagulation factor 2 (F2). However, these biomarkers are affected by several factors such as age, sex, inflammation, and other underlying diseases. ¹⁹⁴ In order to measure the CC systematically, systematic scoring methods have been evolved including the CC scoring system (CASCO), the modified Glasgow prognostic score (mGPS), and the cachexia staging score (CSS). The score corresponds with either non-malignant CPC or CC and RC and effectively predicts the survival of CC patients.^194–197 More recently, Anderson et al. demonstrated that CC patients display reduced total lean body mass, stair climb power (SCP), upper body strength, and bioavailable testosterone, and increased REE, cytokines levels, and fatigue compared to the cancer patients without cachexia and weight stable patients without cancer. This study also showed that SCP is a better marker of CC with 78% sensitivity and 77% specificity at a cut-off of 336 watts. ¹⁹⁸

Over the years, studies have proven that CC can be differentiated from the underlying other muscle wasting disorders by the mechanical characteristics, and the targeted therapies that prevented CC prolonged the survival and improved the quality of life, while tumor cells continue to propagate.^143,199 Multidimensionality of CC demands personalized and systematized treatment strategies. Nevertheless, RC is rebellious to treat, and palliative treatments are often preferred over the other therapy options. The first line of choice to prevent further deterioration during CC is to treat the patients with catabolism inhibitory drugs alongside nutrition supplementation, exercise, and psychological counseling.^2,200,201 Table 3 and Figure 2 summarize drugs under various clinical trials and their mechanisms.^{91,92,100–102,174,199,202–219}

OPEN IN VIEWER

Table 3.

Preclinical and clinical trials to treat cachexia.

Cancer type	Drug or treatment	In vitro/in vivo/clinical	Model	Mechanism of outcome	References
Breast	Vitamins—riboflavin, Niacin, coenzyme Q10	In vivo	Sprague-Dawely rats	↑ Krebs cycle, oxidative phosphorylation	202
	Silibinin	In vitro	MDA-MB-231, MDA-MB-468, BT549, BT474, SKBR3 cells	↓anaerobic glycolysis, GLUT-1, HK-II, p-EGFR, c-MYC, stemness ↑cellular biomass	203
Colorectal	AR-42	In vivo	C26 model	↑restoration glycolytic intermediates, KY, GDAP1, KCNH2, ACTC1, FOXO1 ↑PDE4A, TNMD, CASR, SYPL2, IGFBP5 ↓catabolic muscle phenotype, weight loss, glycogen intermediates, ↓IL-6, LIF, EDEM1, FBXO6, XIRP1, CDKN1A, DAXX, MYLK2, NUB1 ↓NUB1	199
	Amelioride	In vivo	CT26 model	↑PDK4 ↓exosome release from tumors, muscle atrophy, catabolism, glycolysis, OXCT1, BDH2	91
	Lithium chloride	In vitro	C2C12 cells	↑ myocyte differentiation, MyHC, GSK3β ↓Pax-7, atrogin-1, IL-1β, IL-6, iNOS	204
		In vivo	CT26 model	↑body weight ↓ atrogin-1, MURF1, iNOS, muscle wasting, tumor growth	204
	GW4869	In vitro	HCT-116 cells	↑Leptin, ADIPSIN ↓exosome secretion, UCP1, PRDM16, WAT browning	100
	GW4869	In vivo	C26 model	↑Bcl-2 ↓exosomes, miR-195a-5p, miR-125b-1-3p, muscle atrophy	101
	ACVR2B/Fc	In vivo	HCT-116 model	↑muscle strength and function, cardiac strength ↓ fat loss, bone loss,	205
	Cryptotanshinone	In vitro	C2C12 cells	↓ atrogin-1, MURF1, STAT3, atrophy	206
		In vivo	CT26 model	↓STAT3, atrogin-1, MURF1, weight loss, muscle wasting	206
Lung	Alpinetin	In vitro	LLC cells	↓E3 ubiquitin ligase, atrogin-1, MURF1, myoatrophy	207
		In vivo	C57BL/6	↑body weight, PPAR-γ↓spleen weight, IL-1β, NF-κB	207
	Anamorelin	Phase II trial	Advanced NSCLC patients	↑ lean body mass, body weight	208
Melanoma	Isoliquiritigenin	In vitro	A375 cell line	↓glucose uptake, lactate levels, GLUT1, HK-II, ATP, mTOR, p-mTOR, RICTOR, p-Akt, p-GSK3β↑oxygen consumption	209
	Metformin, teneligliptin, vildagliptin, empagliflozin, dapagliflozin	In vivo	B16F1 mouse melanoma cells	↑ body weight, feed intake, water intake, serum GLP-1, glycogen storage skeletal muscle weight, locomotor count, perirenal fat, visceral fat, subcutaneous fat, serum triglyceride, serum HDL, serum VLDL ↓ ghrelin, TNF- α, IL-6, CRP, serum glucose, serum insulin, serum LDH, liver weight/body weight ratio, kidney weight/body weight ratio, spleen weight/ body weight ratio, muscle fibrosis	210
Pancreatic	Silibinin	In vitro	S2-013, T3M4,PANC-1, BxPC-3,AsPC-1, MiaPaCa-2	↓c-MYC, STAT3	211
		In vivo	Orthotopic nude mice	↑body weight↓c-MYC, p-STAT3, GLUT-1, MURF1, atrogin-1, myofiber degradation, TNF-α, IL-6	211
	Bergamotiin	In vitro	Pancreatic cancer cell conditioned C2C12, 3T3L1	↑MyHC, aP2, adiponectin, resistin↓MURF1, atrogin-1, cell viability, LC3-II, p-STAT3, p-FOXO4, p-Akt, ZAG, HSL	212
		In vivo	MiaPaCa-2 cells	↑body weight, C/EBP- α, PPAR-γ↓atrophy, MURF1, atrogin-1	212
	SP600125	In vitro	Pancreatic cancer cell conditioned C2C12	↓TRIM63, FBXO32, myotube atrophy, myosin heavy chain turnover	213
		In vivo	Orthotopic cachexiaMouse model	↑forelimb grip strength, body weight, carcass weight, gastrocnemius weight↓TRIM63, FBXO32	213
Other	BotryosphaeranMonoclonal AntibodyAgainst GFRAL(3P10)	In vivo	Walker-256 model	Corrected insulin resistance, normalized glucose and cholesterol levels↑leukocytes, lymphocytes↓tumor growth, cachexia	214
		In vivo	Patient-derived xenograft model	↑forelimb grip strength, body weight↓FOXO32, BNIP3, GADD45A, lipid mobilization and oxidation	215
	Indomethacin	In vivo	C57BL/6J	↑food intake, weight↓ IL-1α, IL-1β, IL-2, TNF-α,	216
	Ghrelin	In vivo	F344/NTafBR	↑weight gain, lean body mass, neuropeptide Y, agouti gene-related peptide↓ IL-1β,	174
	Megestrol acetate	Clinical trial	Cachectic cancer patients (n = 133)	↑weight gain, appetite, food intake	217
	Cannabinoids	Clinical trial	Advanced stage cancer patients (n = 24)	↑food intake, appetite, quality of sleep, improved chemosensory perception	218
	Celecoxib	Clinical trial	Cachectic cancerPatients (n = 11)	↑BMI, body weight, quality of life, physical performance	219

GLUT-1: glucose transporter 1; HK-II: hexokinase 2; p-EGFR: phospho epidermal growth factor receptor 1; c-MYC: c-MYC proto oncogene; KY: kyphoscoliosis peptidase; GDAP1: ganglioside induced differentiation associated protein 1; KCNH2: potassium voltage gated channel subfamily H member 2; ACTC1: actin alpha cardiac muscle 1; PDE4A: phosphodiesterase 4A; TNMD: tenomodulin; CASR: calcium sensing receptor; SYPL2: synaptophysin 2; IGFBP5: insulin like growth factor binding protein 2; IL-6: interleukin-6; LIF: leukemia inhibitory factor; EDEM1: ER degradation enhancing alpha mannosidase-like protein 1; FBXO6: F-box protein 36; XIRP1: xin actin binding protein repeat containing 1; CDKN1A: cyclin-dependent kinase inhibitor 1A; DAXX: death domain associated protein; MYLK2: myosin light chain kinase 2; NUB1: negative regulator of ubiquitin-like proteins 1; MyHC: myocin heavy chain; GSK3β: glycogen synthase kinase 3 beta; p-GSK3β: phosphoglycogen synthase kinase 3 beta; Paired box 7; IL-1β: interleukin-1 beta; iNOS: inducible nitric oxide synthase; MURF1/TRIM63: muscle-specific RING finger protein 1/tripartite motif containing 63; UCP1: uncoupling protein 1; PRDM16: PR/SET domain 16; WAT: white adipose tissue; Bcl-2: B-cell CLL/lymphoma 2; STAT3: signal transducer and activator of transcription 3; p-STAT3: phospho signal transducer and activator of transcription 3; NF-κB: nuclear factor kappa—light chain enhancer of activated B cells; ATP: adenosine triphosphate; mTOR: mechanistic target of rapamycin kinase; p-mTOR: phospho mechanistic target of rapamycin kinase; TNF-α: tumor necrosis factor–alpha; CRP: C-reactive protein; GLP1: glucagon like peptide 1; HDL: high-density lipoprotein; VLDL: very low density lipoprotein; RICTOR: RPTOR independent companion of mTOR complex 2; Akt1: Akt serine/threonine kinase 1; p-Akt1: phospho Akt serine/threonine kinase 1; LC3bII/LC3BI: light chain 3 B 1/light chain 3 B 2; p-FOXO4: phospho Forkhead box O4; ZAG: zinc-alpha-2 glycoprotein; HSL: hormone sensitive lipase; C/EBP- α: CAAT enhancer binding protein alpha; PPARγ: phospho peroxisome proliferator-activated receptor gamma; FBXO32: F-box protein 32; BNIP3: Bcl-2 interacting protein 3; GADD45A: growth arrest and DNA damage inducible alpha.

OPEN IN VIEWER

Figure 2.

Molecular insight to cachexia and mechanism of cancer cachexia inhibition by various drugs. The figure was created in BioRender.com. (A color version of this figure is available in the online journal.)

ASCO guidelines recommend dietary assessment and psychological counseling as a crucial part of the treatment besides the drug-based treatments. ²²⁰ Artificial feeding with priority given to the enteral route has been the preferred way to treat terminally ill cancer patients. ²²¹ It is becoming increasingly obvious that cancer cachexia is a multiorgan disease involving a variety of causes, and hence needs combined therapeutic approaches such as nutrient supply, physical activity, and drugs for its management. ²²² Nutritional supplementation is inevitable in cancer patients, as food intake is compromised secondary to anorexia, oral mucositis, and vomiting. ²²³ For effective anabolic resistance, an increase in caloric intake of 300–400 kcal/day and 50% extra protein intake is essential. ²²⁴ High calorie and proteinaceous diet along with oral supplementation of β-hydroxy-β-methyl butyrate (HMB), omega-3 fatty acids, L-carnitine, and eicosatetraenoic acid have shown to be beneficial in patients with CPC and CC.^225–229 A study conducted on lung cancer patients showed that oral administration of omega-3 fatty acids increases lean body mass and improves the cachectic conditions in these patients. ²³⁰ In addition, pharmacological agents such as those that target proinflammatory cytokines, non-steroidal anti-inflammatory drugs (NSAIDs), and cannabinoids have been widely used to treat CC. ²²⁴ Anti-TNF-α agents such as etanercept and infliximab, thalidomide, and pentoxifylline showed a modest gain in lean body mass with no noteworthy clinical benefits.^{15,16,231–235} Clazakizumab humanized anti-IL-6 monoclonal antibody increased the hemoglobin and ALB levels and relieved fatigue in advanced-stage cancer patients. ²³⁶ Administration of ghrelin daily for 8 weeks in low dose (0.7µg/kg body weight) or high dose (13µg/kg body weight) subcutaneously improved the appetite and reduced fat loss in gastrointestinal cancer patients. ²³⁷ In a phase II randomized clinical trial, intravenous administration of ghrelin increased the food intake and appetite and reduced chemotherapy-induced nausea in esophageal cancer patients. ²³⁸ In addition, progesterone derivatives including megestrol and medroxyprogesterone have been shown to inhibit proinflammatory cytokines such as TNF-α, IL-6, and IL-1 thereby reducing cancer-related anorexia and cachexia.^239–241 Various corticosteroids such as dexamethasone (3–6 mg/day), methylprednisolone (12 mg/day), and prednisone (15 mg/day) have been shown to increase appetite and weight gain in cancer patients.^242,243 However, these hormonal derivatives have shown long-term side effects, including insulin resistance, myopathy, fluid retention, adrenal inefficiency, and sleep disorders.^243,244 In addition, administration of NSAIDs such as celecoxib showed a significant increase in body weight, BMI, and quality of life in head and neck and gastrointestinal cancer patients. ²¹⁹ A phase III clinical trial showed that administration of phytocannabinoid, tetrahydrocannabinol (THC), increases appetite, body fat, body weight, and quality of life. ²⁴⁵ Recent studies have shown that Kampo medicine, a traditional Japanese medicine, improves CC condition.^247–249 Kampo formulae including Hochuekkito (HET), Juzentaihoto (JTT), Ninjin’yoeito (NYT), Seishoekkito (SET), Shosaikoto (SSK), and Rikkunshito (RKT) improved appetite, anemia, protein synthesis, ghrelin levels, and reduced protein breakdown, inflammation, and adipose tissue loss in various preclinical and clinical settings of CC.^248–259

Recently, in December 2020, Japan approved anamorelin (non-peptide ghrelin analog) for cancer cachexia treatment based on phase II trials conducted in Japanese advanced gastrointestinal and lung cancer patients, creating the hope for the development of novel drugs.^208,260,261 In addition, physical exercise has shown beneficial effects, including reduced systemic inflammation, reduced catabolism, and preserving muscle mass in CC patients along with psychological stability.^262–264 Recent studies have highlighted the considerations for multimodal treatment protocol owing to the complexity of pathogenesis in CC. A phase II clinical trial conducted by Solheim et al. ²⁶⁵ used oral nutritional supplements, resistance training, and celecoxib for CC in patients with incurable lung and pancreatic cancers. Next, a randomized controlled clinical trial by Uster et al. ²⁶⁶ implementing nutritional supplements with 60 min of exercise twice a week showed increased protein intake, and reduced nausea and vomiting in palliative cancer patients. Since no major side effects were observed during these studies, multimodal treatment approaches might be considered safe and feasible.

Lack of adequate early diagnosis, prognosis, and therapeutic algorithms creates great difficulty in preventing cachexia development and effective treatments during cancer progression.

Conclusions

Overall, progressive cachexia has deleterious and lethal consequences for cancer patients. The widespread failure of upliftment of CC patients by the usage of anti-cancer therapies led to the realization that critical mediators and mechanisms that induce cachexia could be distinct from those that drive primary tumor progression and metastasis. As mentioned earlier, our current knowledge about cachexia is widely accepted from the studies on genetically engineered and orthotopic animal cachexia models which do not recapitulate systemic and molecular changes occurring in CC patients. Moreover, the vast majority of murine models used for studying CC are LLC in C57BL/6, colon-26 in Balb/c, tumor cell injection, and transgenic mice C57BL/6 APC^+/min models. Different strains and different cancer types need to be employed to reveal the relevant cachectic mechanisms. Nevertheless, these observations prompt future studies to aim for screening of relevant early diagnostic and prognostic biomarkers and clinical validation of promising therapies that can effectively treat cachexia alongside the tumor. In addition, it is important to distinguish precachexia from anorexia and later-stage cachexia events. Present knowledge gained from animal studies and a few clinical studies are insufficient to comment on potential mediators of precachexia alone and is a subject of future investigations. Clinical trials on RC patients are lacking due to increased dropout, missing data, and avoiding issues of confounding death. Currently, there is no standard therapy that can effectively reverse the CC. Given the complexity of CC, rigorous preclinical studies in the context of etiology, initiation, progression, and therapy followed by robust clinical validation are all warranted for the effective management of CC.